Hypomethylating agents, such as azacytidine and decitabine, have demonstrated efficacy in treating individuals with TET2-mutant myeloid malignancies and warrant investigation for their potential to prevent AF in patients with CHIP. This evidence concerns the gene TET2 and atrial fibrillation.